133111-56-5Relevant articles and documents
Investigations on cytotoxicity and anti-inflammatory potency of licofelone derivatives
Liu, Wukun,Zhou, Jinpei,Bensdorf, Kerstin,Zhang, Huibin,Liu, Haoran,Wang, Yubin,Qian, Hai,Zhang, Yanchun,Wellner, Anja,Rubner, Gerhard,Huang, Wenlong,Guo, Cancheng,Gust, Ronald
scheme or table, p. 907 - 913 (2011/04/19)
A series of C5-substituted licofelone ([2,2-dimethyl-6-(4-chlorophenyl)-7- phenyl-2,3-dihydro-1H-pyrrolizin-5-yl]acetic acid) derivatives were developed by a parallel synthesis approach and investigated for cytotoxicity against MCF-7 and MDA-MB-231 cells as well as for anti-inflammatory potency in vitro and in vivo. Dependent on the C5-substituent, the compounds showed high selectivity for MCF-7 cells. Especially 2-oxoethyl benzoate derivatives were inactive at the MDA-MB-231 cell line and as active as 5-FU at MCF-7 cells. C5-acetyl (8a), -2-oxoethyl formiate (8e), -2-oxoethyl acetate (8f) and -2-oxoethyl propionate (8g) derivatives showed growth inhibition at both cell lines, comparable with cisplatin. Modifications significantly reduced the inhibitory potency at COX-1 and COX-2 in vitro and in the xylene-induced ear swelling assay in mice. Only compound 8a was equipotent to licofelone, ibuprofen and celecoxibe in vivo.
Licofelone-nitric oxide donors as anticancer agents
Liu, Wukun,Zhou, Jinpei,Liu, Yinglin,Liu, Haoran,Bensdorf, Kerstin,Guo, Cancheng,Gust, Ronald
scheme or table, p. 487 - 493 (2011/10/18)
Five licofelone ([2,2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2,3-dihydro-1H- pyrrolizin-5-yl]acetic acid) nitric oxide donor conjugates were developed by a parallel synthesis approach. The biological screening revealed that compounds with a propyl (6b), butyl (6c), or octyl (6d) chain between licofelone and the nitric oxide donor exhibited high antiproliferative potency at MCF-7 and MDA-MB-231 breast cancer as well as at HT-29 colon cancer cells. Moreover, 6b-d possessed at least 2-fold higher cytotoxicity at MDA-MB-231 cells than the parent compound licofelone although they showed less inhibitory activity at COX-1 and COX-2. A correlation between COX inhibition and growth inhibitory properties is not visible. However, the high levels of nitric oxide production of the compounds may result in their high cytotoxic activity. Non-steroidal anti-inflammatory drugs possessing nitric oxide donors are promising anti-inflammatory and anticancer drugs. Herein, a series of licofelone-nitric oxide donors was synthesized and evaluated for their primary biological activities.
Synthesis and biological evaluation of licofelone derivatives as anticancer and anti-inflammatory agents
Liu, Wukun,Zhou, Jinpei,Zhang, Huibin,Qian, Hai,Yin, Jiahan,Bensdorf, Kerstin,Gust, Ronald
experimental part, p. 911 - 917 (2012/07/03)
Two C5-substituted licofelone derivatives were developed and investigated for cytotoxicity against mammary (MCF-7 and MDA-MB 231) as well as colon carcinoma (HT-29) cancer cells. Both compounds were at least 2-fold more active than 5-fluorouracil (5-FU) and licofelone against mammary carcinoma cells. At HT-29 cells, they were less active, but nevertheless distinctly as active as 5-FU and still 2-fold more active than licofelone. However, variation of the C5- carboxylic group results in an occasionally remarkable decrease of anti-inflammatory potency in in vitro and in vivo.
An efficient synthesis of 6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3- dihydro-lh-pyrrolizine, a key intermediate in the licofelone synthesis
Radl, Stanislav,Stach, Jan,Cerny, Josef,Klecan, Ondrej
experimental part, p. 1011 - 1022 (2010/02/27)
An efficient synthesis of 6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3- dihydro-1H-pyrrolizine, a key intermediate for the synthesis of licofelone, an anti-inflammatory drug currently undergoing evaluation of the phase-III clinical studies, is described. The method is based on a novel synthesis of unstable 5-benzyl-3,3-dimethyl-3,4-dihydro-2H-pyrrole, which is then treated with 2-bromo-1-(4-chlorophenyl)ethan-1-one. 2,2-Dimethyl-5-phenylpent-4-ynal with benzylamines provides the corresponding Schiff bases. Migration of the C=N double bond in these N-(2,2-dimethyl-5-phenylpent-4-yn-1-ylidene)benzylamines into conjugation with the aromatic ring using various base/solvent systems was studied. Acid hydrolysis of the formed Schiff bases then provided 2,2-dimethyl-5-phenylpent-4-yn-1-amine and 2,2-dimethyl-5-phenylpenta-3,4-dien- 1-amine; their ratio was influenced mainly by the reaction conditions. Cyclization of these amines using Ag or Au catalysts then led to 5-benzyl-3,3-dimethyl-3,4-dihydro-2H-pyrrole.
Arylpyrrolizines as inhibitors of microsomal prostaglandin E2 synthase-1 (mPGES-1) or as dual inhibitors of mPGES-1 and 5-lipoxygenase (5-LOX)
Liedtke, Andy J.,Keck, Peter R. W. E. F.,Lehmann, Frank,Koeberle, Andreas,Werz, Oliver,Laufer, Stefan A.
scheme or table, p. 4968 - 4972 (2010/03/03)
We synthesized and evaluated inhibitors for the microsomal prostaglandin E2 synthase-1 (mPGES-1), based on the arylpyrrolizine scaffold. In a cell free mPGES-1 assay several "sulfonimides" exceeded our leadML3000 (3) in potency. The most promising compound, the tolylsulfonimide 11f, revealed an IC50 of 2.1 μM and is equipotent to the literature reference molecule MK886 (1). Selected compounds also potently reduced 5-LOX product formation in intact cells. Inhibition of isolated COX was occasionally remarkably cut down.
PROCESS FOR THE PREPARATION OF 6-(4-CHLOROPHENYL)-2,2-DIMETHYL-7-PHENYL-2, 3-DIHYDRO-1H-PYRROLIZIN-5-YL ACETIC ACID AND ITS INTERMEDIATES
-
Page/Page column 10, (2010/11/28)
The present invention relates to a process for the preparation of 6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2, 3-dihydro-1H-pyrrolizin-5-yl acetic acid, in which the key intermediate, 5-Benzyl-3,3-dimethyl-3,4-dihydro-2H-pyrrole is obtained by the hydrogenation of 2,2-dimethyl-4-oxo-5-phenyl-nitropentane. The invention also relates to the preparation of the intermediates occurring in the above process.
POLYMORPHIC FORM OF 6- (4-CHLOROPHENYL) -2, 2-DIMETHYL-7-PHENYL-2, 3-DIHYDRO-LH-PYRROLIZIN-5-YLACETIC ACID
-
Page/Page column 1; 9; 11-14, (2008/06/13)
The present invention relates to a new crystalline modification of 6- ( 4-chlorophenyl) -2, 2-dimethyl-7- phenyl-2, S-dihydro-lH-pyrrolizin-S-ylacetic acid which is referred to as polymorph B. It has a peak in the solid state 13C-NMR spectrum (with adamantane as external reference standard; CH group d = 29.45 ppm) in the range from 179.8 to 180.2 ppm and can be processed directly to a pharmaceutical formulation.
Synthetic studies towards ML-3000: A concise synthesis of this non- steroidal anti-inflammatory drug
Cossy, Janine,Belotti, Damien
, p. 5145 - 5156 (2007/10/03)
ML-3000 was obtained from 1-chloro-3-phenyl-2-propyne in 8 steps with an overall yield of 19%. The key steps are a thermal acid-promoted bicyclization of an ω-acetylenic amino ester and a Suzuki cross-coupling reaction between a heteroaryl triflate and (4-chlorophenyl)boronic acid.
(6,7-Diaryldihydropyrrolizin-5-yl)acetic Acids, a Novel Class of Potent Dual Inhibitors of Both Cyclooxygenase and 5-Lipoxygenase
Laufer, Stefan A.,Augustin, Jan,Dannhardt, Gerd,Kiefer, Werner
, p. 1894 - 1897 (2007/10/02)
A novel class of nonantioxidant dual inhibitors of both CO and 5-LO is described.The balance between the activity against CO and 5-LO can be shifted by modifying the substitution pattern of the phenyl moiety at the 6-position of the pyrrolizine ring.Structure-activity relationships are discussed.Compound 3e with a 4-Cl substituent (IC50 = 0.21 μM (CO); 0.18 μM (5-LO)) and 3n with a 4-OCH3 substituent (IC50 = 0.1 μM (CO); 0.24 μM (5-LO)) are the most potent and well-balanced dual inhibitors of both enzymes.The inhibition of CO was determined in a bovine thrombocyte intact cell assay and that of 5-LO using intact bovine PMNL.Compound 3e was also ivestigated in human cells.
